Silicon Dioxide Coated Virus-Like Particle Vaccine Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, particularly aluminum salts, are limited in enhancing cellular immunity and often complicate vaccine production with additional excipients, necessitating a simpler method to induce a balanced immune response for infectious disease prevention and treatment.
Innovation Solution
A silicon dioxide vaccine delivery system using virus-like particles as templates, where silicon dioxide is coated onto these particles to form nanoparticles, acting as both antigens and adjuvants, facilitating a balanced immune response through a straightforward nano-silicon dioxide synthesis method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aluminum salt adjuvants are used to enhance immune response, then humoral immunity is improved, but cellular immunity cannot be improved and production becomes complicated due to additional excipients
Solution Approach 1:
The patent combines the antigen (virus-like particles) and adjuvant (silicon dioxide) into a single integrated nanoparticle system. The silicon dioxide is coated directly onto the virus-like particles, creating a unified structure that eliminates the need for separate excipients and simplifies production while maintaining both humoral and cellular immunity enhancement capabilities
Solution Approach 2:
The vaccine system uses a composite material structure consisting of virus-like particles coated with silicon dioxide. This composite nanoparticle combines the immunogenic properties of the viral antigen with the adjuvant effects of silicon dioxide, creating a single material that performs multiple functions (antigen delivery + immune enhancement) without requiring additional excipients
2Ease of manufacture
If simple aluminum salt adjuvants are used, then production is simpler, but cellular immunity enhancement is insufficient
Solution Approach 1:
The composite nanoparticle structure of virus-like particles coated with silicon dioxide provides both manufacturing simplicity and enhanced cellular immunity. The single-step coating process maintains ease of production while the silicon dioxide component specifically enhances cellular immunity response, overcoming the limitations of simple aluminum salts
3Reliability
If excipients are added to improve antigen-adjuvant interaction, then immune response is enhanced, but production process becomes complicated
Solution Approach 1:
The patent merges the antigen and adjuvant into direct contact through coating silicon dioxide onto the virus-like particles. This physical integration ensures optimal antigen-adjuvant interaction without requiring additional excipients to mediate the interaction, thereby simplifying the production process while maintaining enhanced immune response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively induces both humoral and cellular immunity, demonstrated by in-vivo experiments, offering a stable and efficient vaccine platform with uniform particle sizes and good stability for various infectious diseases.
Implementation Method 1
silicon dioxide is coated on surfaces of the virus-like particles to form nanoparticles
Implementation Method 2
adjuvants play an extremely important role in enhancing the immune response to antigens
Data Source
AI summary
A silicon dioxide vaccine delivery system uses virus-like particles as templates. The particle morphology of the silicon dioxide vaccine system is 50-500 nm of nanoparticles, of which an antigenic component is 20-200 nm of virus-like particles, an adjuvant component is nano silicon dioxide, the silicon dioxide component is wrapped on the surface of the virus-like particle, and a mass ratio of silicon element to antigen is 50-0.5:1. The construction of the silicon dioxide vaccine delivery system includes steps of: (1) adding a proper amount of 3-aminopropyltriethoxysilane into an aqueous solution containing virus-like particles and stirring; (2) adding a proper amount of tetraethoxysilane into the dispersion system in step (1) and stirring; and (3) centrifuging a reactant obtained in step (2) and removing a supernatant to obtain a product. A vaccine constructed by means of the vaccine system can trigger a host to generate humoral and cellular immune levels.